An IRB approved Retrospective Chart Review Study of adult solid tumor patients treated with nivolumab or pembrolizumab at a single institution

Trial Profile

An IRB approved Retrospective Chart Review Study of adult solid tumor patients treated with nivolumab or pembrolizumab at a single institution

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top